Voxzogo (Vosoritide)
Out of stock
We will notify you as soon as it becomes available.
-
Description
-
Related Products
-
Related Conditions
Fact Table
| Fact Table | |
|---|---|
| Formula | C176H290N56O51S3 |
| License | US DailyMed |
| Bioavailability | Unknown |
| Legal status | Prescription drug |
| Chemical Name | Vosoritide |
| Elimination half-life | 21.0 to 27.9 minutes |
| Dosage (Strength) | 0.4 mg; 0.56 mg; 1.2 mg |
| Pregnancy | Consult a doctor |
| Brands | Voxzogo |
| Protein binding | Unknown |
| PubChem CID | Not available because this is not a discrete structure |
| MedlinePlus | a622012 |
| ChEBI | Not Assigned |
| ATC code | M05BX07 |
| DrugBank | DB11928 |
| KEGG | D11190 |
| Routes of administration | Subcutaneous injection |
Voxzogo, scientifically known as Vosoritide, marks a groundbreaking advancement in treating Achondroplasia, the most common form of dwarfism. As a synthetic analog of C-type Natriuretic Peptide (CNP), Voxzogo stimulates bone growth in children and adolescents who are still growing. This innovative medication offers hope to those affected by Achondroplasia, aiming to improve their quality of life by addressing the genetic condition at its root.
Before you buy Voxzogo, you must talk to your healthcare provider about potential side effects and Voxzogo price.
Directions
Before administering Voxzogo, ensure that the patient is well-hydrated and has adequate food intake.
The recommended Voxzogo dosing is based on the patient's actual body weight.
Voxzogo is administered subcutaneously once daily.
Reconstitute the lyophilized powder in a single-dose vial according to the instructions provided. The injection volume depends on the patient's weight and the concentration of reconstituted Voxzogo.
Monitor growth closely and adjust the dosage based on the patient's actual body weight. Discontinue treatment upon closure of epiphyses.
Ingredients
Voxzogo contains vosoritide as its active ingredient.
Cautions
Before starting Voxzogo, patients should undergo a thorough medical evaluation.
Caution is advised for individuals with underlying heart conditions, as Voxzogo can influence blood pressure and heart rate.
It is also important to monitor for signs of allergic reactions to Vosoritide or any of the medication's components.
Pregnant or breastfeeding women should discuss potential risks and benefits with their healthcare provider.
Regular follow-ups and monitoring of growth rates are recommended throughout the treatment period.
Interactions
No specific drug interactions have been reported with Voxzogo. You must inform your healthcare provider about all medications, supplements, or herbal products you are taking.
Side Effects
The most common adverse reactions associated with Voxzogo include:
- Injection site erythema
- Injection site swelling
- Rash
- Vomiting
- Injection site urticaria
- Arthralgia
- Decreased blood pressure
- Gastroenteritis
Frequently Asked Questions about Voxzogo (Vosoritide)
What is Voxzogo (Vosoritide)?
Voxzogo (Vosoritide) is a C-type natriuretic peptide (CNP) analog that increases linear growth in pediatric patients with achondroplasia with open epiphyses.
How does Voxzogo work?
Voxzogo works alongside the body’s natural CNP to stimulate the CNP signaling pathway to promote bone growth.
Who can use Voxzogo?
Voxzogo is intended for children aged five years and older whose growth plates are still open.
How is Voxzogo administered?
Voxzogo is taken daily as an injection under the skin, administered by a caregiver after a healthcare provider determines the caregiver can assist Voxzogo.
What are the common side effects of Voxzogo?
The most common side effects include injection site reactions, high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomach ache.
Are there any contraindications for Voxzogo?
There are no known contraindications for Voxzogo.
What precautions should be taken before administering Voxzogo?
To reduce the risk of decreased blood pressure and associated symptoms, patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving Voxzogo.
What is the dosage form and strength of Voxzogo?
Voxzogo is available for injection in strengths of 0.4 mg, 0.56 mg, or 1.2 mg of vosoritide as a lyophilized powder in a single-dose vial for reconstitution.
